Evolving pet owner expectations demand new models of engagement. Susan Groeneveld shares how Sylvester.AI is pioneering direct-to-consumer pathways to connect with owners, strengthen veterinary partnerships, and unlock commercial scale. 

Securing non-dilutive capital can be the key to bridging the gap between research and commercial reality for agtech startups. Matt Dobbs shares how AgSenze leveraged grant programmes including Innovate UK and EU Horizon to de-risk R&D, unlock private investment, and provide a launchpad of scaling HerdVision.

Advancing a new therapeutic class to market requires a balance of strong science, solid IP protection, and a regulatory path that supports early access. Hunter Land (CEO) shares how Lupvindol is progressing its CBD–corticosteroid combinations for canine IBD and equine osteoarthritis through compelling efficacy data, robust patent strategy, and the FDA’s expanded conditional approval route.

When innovation moves faster than policy, the path to market calls for creative approaches. Tammie Wahaus, CEO of ELIAS Animal Health, shares how her team advances pivotal trials, adapts human health technologies, and keeps development on track as regulatory expectations continue to evolve.

Securing $20 million in Series A funding just five months after its seed round, Lupa is redefining how AI transforms veterinary practice. Nicolo Frisiani, CEO of Lupa, shares how clear traction, rapid revenue growth, and a focus on customer success built strong investor confidence.

Scaling livestock technology requires uniting innovation with effective distribution and farmer adoption. David Smith outlines how Ceres Tag’s open platform empowers universities, distributors, and next-generation producers to accelerate global adoption and data-driven impact.